Actinium Pharmaceuticals Gets Canadian Approval for Two Patents

Dow Jones

05/30

By Katherine Hamilton

Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs.

The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT.

Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe.

Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 29, 2026 17:57 ET (21:57 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2639670451"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2639670451\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2639670451?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-30 05:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639670451","market":"nz","top_or_hot":-1,"title":"Actinium Pharmaceuticals Gets Canadian Approval for Two Patents","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs. \n</p>\n<p>\n  The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT. \n</p>\n<p>\n  Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe. \n</p>\n<p>\n  Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 17:57 ET (21:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinium Pharmaceuticals Gets Canadian Approval for Two Patents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinium Pharmaceuticals Gets Canadian Approval for Two Patents\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-30 05:57</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs. \n</p>\n<p>\n  The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT. \n</p>\n<p>\n  Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe. \n</p>\n<p>\n  Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 17:57 ET (21:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2639670451","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639670451","pubTimestamp":1780091820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs.The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT.Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe.Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATNM":"Actinium Pharmaceuticals, Inc."},"translate_title":"Actinium Pharmaceuticals两项专利获得加拿大批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATNM":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Actinium Pharmaceuticals said it received approval from Canadian regulators for two patents for treatment programs. \n\n\n  The Canadian Intellectual Property Officer issued notices of allowances for applications for Actimab-A and Iomab-ACT. \n\n\n  Actimab-A works in combination with CLAG-M chemotherapy to treat the blood cancer Acute Myeloid Leukemia. A counterpart patent granted in Japan, with applications pending in the U.S. and Europe. \n\n\n  Iomab-ACT is designed as a targeted conditioning agent to enable adoptive cell therapies. The treatment already has a patent in the U.S., with additional applications pending in the U.S., Europe and China. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2026 17:57 ET (21:57 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}